IL—2激活的肿瘤浸润性淋巴细胞与LAK细胞体内外抗肿瘤作用的比较

Comparison of in vitro and in vivo antitumor activity between tumor—infiltrating lymphocytes (TIL) and LAK cells

本文对TIL与LAK细胞的体外,体内抗肿瘤作用进行了比较。发现TIL对自体肿瘤细胞有选择性地杀伤作用,其杀伤活性强于LAK细胞,但TIL对其他无关的肿瘤细胞的杀伤作用弱于LAK细胞,其对ConA诱导的正常淋巴母细胞无杀伤作用,而LAK细胞对比正常细胞有一定的杀伤作用。能特异性阻断抗B16黑色素瘤细胞CTL活性的单抗能抑制来自B16黑色素瘤的TIL对B16细胞的杀伤作用,提示TIL中富含CTL。体内试验证明,就单个细胞能力来讲,TIL的抗肿瘤作用确比LAK细胞强且对LAK细胞治疗无效的晚期肿瘤仍有一定的治疗效果。本研究证明TIL比LAK细胞更适合应用于肿瘤的过继免疫疗法。

It was demonstrated that TILs exhibited higher cytotoxicity to autologous tumor cells than that of LAK cells grown under identical conditions, and TILs had target cell specificity.The cytotoxicity of TILs to other tumor cells was lower than that of LAK cells, and TILs had no cytotoxicity to ConA-induced lymphoblast cells but LAK cells did have some cytotoxicity to the normal cells. The cytotoxicity of TILs to B 16 melanoma cells was reduced by monoclonal antimelanoma antibodies (M2590 and M562) which can block the activity of antimelanoma CTL, suggesting TILs contained high level of CTL activity. TILs were found to be more effective in their therapeutic potency in vivo on a percell basis than were LAK cells. These results indicate that TILs are more suitable to the adoptive immunotherapy of turn or as effector cells than LAK cells.